Content Type: Article

  • IRS Reasserts That Forgivable PPP Expenses Are Not Deductible, but Is Legislative Relief on the Way?

    IRS Reasserts That Forgivable PPP Expenses Are Not Deductible, but Is Legislative Relief on the Way?

    ARTICLE / CLIENT ALERT

    IRS Reasserts That Forgivable PPP Expenses Are Not Deductible, but Is Legislative Relief on the Way?

    December 16, 2020

    Read time: 5 min

    Key takeaways
    Overview

    Loans under the Payroll Protection Program (PPP) are eligible for forgiveness depending upon whether and when the loan proceeds are used for qualified business expenses. One of the benefits of this program is that there is no taxable income for the borrower upon loan forgiveness. While many borrowers were expecting to deduct business expenses as would be the case if there has not been a PPP loan, the US Department of the Treasury’s (Treasury) position has been that PPP expenses resulting in loan forgiveness cannot be deducted for federal income tax purposes due to the tax benefit rule under Code Section 265. See discussion of Notice 2020-32 in our previous client alert, “IRS to deny deductions relating to PPP loans.” A PPP loan can generally be used for payroll costs, interest on mortgage obligations, rent and utilities, which may or may not qualify for loan forgiveness under US Small Business Administration (SBA) rules and guidance. Other types of expenses that can be paid with PPP loans, such as interest on other types of existing debt obligations, cannot qualify for loan forgiveness.

    In depth

    There has been discussion after Notice 2020-32 as to whether Section 265 applies to deny a tax deduction for PPP expenses incurred in 2020 if the application for loan forgiveness is not filed as of the end of the year. Practitioners questioned if Section 265 could apply to PPP expenses when the eligibility to take the PPP loan, and the extent to which the PPP loan will be forgiven, is not established before the end of the taxable year. Among other things, a PPP loan can be used for expenses that do not qualify for loan forgiveness, and the amount of loan forgiveness can be reduced under complicated rules that remain unclear.

    In Rev. Rul. 2020-27, however, Treasury reiterated its position by concluding that the tax benefit rule applies to PPP expenses paid with the proceeds of a PPP loan irrespective of when the PPP loan is forgiven so long as the taxpayer reasonably expects that the loan proceeds used to pay PPP expenses will eventually be forgiven. The Internal Revenue Service (IRS) states in this ruling that the timing of the forgiveness of the loan is not relevant because Section 265(a) turns on whether a deduction is allocable to a class of tax-exempt income without regard to whether such income is received or accrued. Many employers that have had difficulty understanding the ever-changing rules under PPP may find it particularly irksome that this ruling describes the existing loan forgiveness procedures as “clear and readily accessible guidance”. If it turns out that a taxpayer paid or incurred PPP expenses in the 2020 taxable year for which no deduction is permitted because, at the end of the 2020 taxable year, the taxpayer reasonably expects to receive forgiveness of the loan, but the taxpayer is unable to subsequently secure loan forgiveness in whole or in part, there is a companion revenue procedure that provides a “safe harbor” under which a taxpayer can claim a deduction in 2020 or in a subsequent year. Read the IRS document “Rev. Pro. 2020-51” to learn more.

    Treasury’s position in Notice 2020-32 and Revenue Ruling 2020-27 has been heavily criticized by employers, practitioners and key legislators that were involved in enacting the Coronavirus Aid, Relief and Economic Security (CARES) Act, including Senate Finance Committee Chair, Chuck Grassley (R-Iowa), Ranking Member Ron Wyden (D. Ore) and Chair of the Ways and Means Committee, Richard E. Neal (D-Mass). While the CARES Act did not expressly address the application of the tax benefit rule, Treasury’s position in pushing a questionable interpretation is puzzling. In particular, it is unclear why Congress would have provided only for tax forgiveness when a tax deduction for many taxpayers might be more valuable from a cash flow perspective, particularly when taking into account that taxpayers may have counted on those deductions when determining 2020 estimated tax payments.

    Relief appears to be on the way from Congress. On December 14, lawmakers unveiled a draft of the Bipartisan Emergency COVID Relief Act of 2020, which includes a provision allowing deductions for PPP expenses that result in PPP loan forgiveness. The proposed legislation would provide, in relevant part, that “[N]o deduction shall be denied or reduced, no tax attribute shall be reduced, and no basis increase shall be denied, by reason of the exclusion from gross income [of the forgiveness of PPP loans].” As the bill’s name suggests, it has received bipartisan support. Moreover, Congress will have to take some action by December 18 to avoid a federal government shutdown. Nonetheless, unless relief is enacted, taxpayers should calculate estimated taxes with the understanding that the IRS will likely challenge the deductibility of expenses that are paid for with PPP loan proceeds and with the understanding that they may need to adjust their calculations depending on whether relief is passed this session.

    Authors

    Andrew C. Liazos

    Partner

    Boston, New York – One Vanderbilt Avenue

    Evan Walters

    Partner

    Chicago

    More insights

  • International News: Restructuring

    International News: Restructuring

    INTERNATIONAL NEWS / REPORT

    International News: Restructuring

    December 2020

    Read time: 2 min

    Key takeaways
    Overview
    In depth
    Authors

    Mark Fine

    Partner

    London – 22 Bishopsgate

    Aymen Mahmoud

    Partner

    London – 22 Bishopsgate

    Emily C. Keil

    Partner

    Chicago

    Giulia Venanzoni

    Counsel

    London – 22 Bishopsgate

    Michael Rostov

    Partner

    Los Angeles

    Daniel Thomson

    Associate

    New York – One Vanderbilt Avenue

    Dr. Uwe Goetker

    Partner

    Düsseldorf

    Sandra P. McGill

    Counsel

    Chicago

    More insights

  • Congress Passes the Corporate Transparency Act—Overriding Presidential Veto

    Congress Passes the Corporate Transparency Act—Overriding Presidential Veto

    ARTICLE / CLIENT ALERT

    Congress Passes the Corporate Transparency Act—Overriding Presidential Veto

    December 15, 2020 (Updated January 7, 2021)

    Read time: 8 min

    Key takeaways
    Overview

    On January 1, 2021, the US Senate joined the House of Representatives in overriding the presidential veto of the National Defense Authorization Act for Fiscal Year 2021, which includes the Corporate Transparency Act (the Act). The Act requires a report be filed with the Financial Crimes Enforcement Network (FinCen) that identifies each beneficial owner of, and applicant forming, a reporting company. While questions remain as to the full implications of the Act, it represents an important step in the right direction for the United States in the battle against money laundering and terrorist financing.

    Read the full article in French, “Le Congrès des Etas-Unis Adopte la Loi sur la Transparence des Entreprises – Annulant le Veto Présidentiel,” in French.

    Read the full article, “El Congreso Americano aprueba la ley de transparencia empresarial, que prevalece sobre el veto Presidencial,” in Spanish.

    In depth

    On January 1, 2021, the US Senate joined the House of Representatives in overriding the presidential veto of the National Defense Authorization Act for Fiscal Year 2021—which includes the Corporate Transparency Act (the Act). The Act requires a report be filed with the Financial Crimes Enforcement Network (FinCEN) that identifies each beneficial owner of and applicant forming a reporting company. The measure brings the United States closer to parity with other developed nations, which have enacted similar mandates.

    A version of the Act has been floating around since the summer of 2017. In May 2019, legislators in both houses of Congress introduced the Corporate Transparency Act of 2019 as S. 1978 and H.R. 2513. The House of Representatives passed its version of the Act in October 2019. The White House issued a statement of administration policy in support of the House bill, but the Senate never acted on it (see Statement of Administration Policy on H.R. 2513 – Corporate Transparency Act of 2019, as amended by Manager’s Amendment, October 22, 2019, available here).

    What is a reporting company?

    A reporting company is defined as a corporation, limited liability company or other similar entity that is created by filing a document with the secretary of state (or an equivalent office) of any state, or formed under foreign law and registered to do business in the United States in a like manner. The Act exempts many categories of companies from the reporting requirement, specifically:

    • Companies that are already subject to supervision or otherwise closely regulated by the federal government (e.g., banks)
    • Dormant companies
    • Companies that employ more than 20 people, filed a tax return reporting gross receipts in excess of $5 million, and have a physical presence in the United States
    • Any entity owned by an entity otherwise exempt

    Who is a beneficial owner and/or an applicant?

    A beneficial owner is defined as an individual who, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise (i) exercises substantial control over an entity or (ii) owns or controls at least 25% of the ownership interests in an entity. A few notable exceptions from the Act include:

    • Minors, provided that information with respect to a parent is otherwise reported
    • An individual acting as nominee, intermediary, custodian or agent on behalf of another individual
    • Persons who control an entity solely because of their employment
    • An individual whose only interest in a reporting company is through a right of inheritance

    An applicant is defined broadly as an individual who files an application to form an entity.

    What information must be reported?

    The report shall include the name, date of birth, current address (business or residential) and unique identifying number from an acceptable document for each beneficial owner and/or an applicant, with an option for such individuals to request and use a FinCEN unique identifying number instead.

    When are new and existing entities required to start furnishing information to FinCEN?

    Reporting obligations for new entities shall begin on the effective date of regulations implementing the Act, which shall be promulgated within one year of enactment. Existing entities will be required to report this information within two years of the effective date of the regulations. The report will be required for newly formed entities at the time of formation. Finally, once regulations are in place, a reporting company will need to update the information provided to FinCEN upon a change in beneficial ownership no later than a year after the change.

    Where is the information stored and who has access to it?

    FinCEN will store the information received pursuant to the Act in a private database not accessible to the public. The information will be made available to Federal and state law enforcement agencies pursuant to an appropriate request—state law enforcement requests require court approval. The Department of the Treasury, the custodian of the records through FinCEN, has its own broad and separate authorization to use the information, including for purposes related to tax administration. Foreign law enforcement also may request information from the database through an appropriate agency of the federal government—but the information will not be subject to any automatic reporting or exchange of information. Finally, financial institutions will have access to the database for customer due diligence purposes.

    Customer due diligence requirements for financial institutions will be updated to conform to the requirements of the Act and to take into account access by financial institutions to the information compiled under the Act. This means that the establishment of any entity account with a financial institution likely will require compliance, by the entity, with the Act—providing a practical barrier to non-compliance.

    What are the penalties for violating the law?

    The willful failure to provide complete and/or updated information required under the Act or willfully providing false or fraudulent information carry steep civil and criminal consequences. Violations carry civil penalties of up to $500 per day that the violation continues and criminal fines up to $10,000 and/or imprisonment for up to two years. The obligations under the Act apply to beneficial owners and to applicants. The unauthorized disclosure of information collected under the Act carries the same civil penalty but a higher criminal penalty of up to $250,000 and a higher maximum term of imprisonment of five years. Unauthorized disclosure includes both a disclosure by a government employee and a disclosure by a third-party recipient of information under the Act.

    Insights

    Unregistered foreign entities. Notably, the Act does not require disclosure of the beneficial owners of a foreign entity if the entity does not register to do business with a state. Presumably, an individual may still be able to access anonymously the US financial or real estate markets using a foreign entity that does not register to do business in a state. It will be interesting to see how the changes to the customer due diligence requirements for financial institutions will affect entities that are not required to file reports under the Act.

    Impact. The Act goes a long way in preventing the misuse of entities to hinder the efforts of law enforcement to combat money laundering. The Act includes a provision prohibiting the issuance of any type of certificate evidencing ownership of such entity in bearer form—a longstanding target of anti-money laundering initiatives. The Act captures indirect ownership; for example, a limited liability company formed by a foreign corporation should have to report the information of a non-US person shareholder of the foreign corporation.

    It remains to be seen how the regulations promulgated under the Act will deal with ownership of a reporting company by trusts, estates and other complex structures commonly used to meet the multijurisdictional requirements of private clients and their families. For example, if a corporation is wholly owned by a bank (which is exempt) as trustee, does the exception for entities owned by other exempt entities eliminate the disclosure requirements for the corporation? How would ownership and/or control be measured with respect to discretionary beneficiaries of trusts? Will the relatively new customer due diligence rules with respect to entities be looked to as a model or will the Report of Foreign Bank and Financial Accounts FBAR rules be used as a standard (31 C.F.R. § 1010.230; 31 C.F.R. § 1010.350)? Using the customer due diligence regulations as a guide, if a trust owns more than 25% of the equity interest in a company, the trustee would be considered the beneficial owner, regardless of whether the trustee is a natural or legal person (31 C.F.R. § 1010.230(d)(3); see also Fin. Crimes Enf’t. Network, FIN-2018-G001, Frequently Asked Questions Regarding Customer Due Diligence Requirements for Financial Institutions (2018)). Presumably, the beneficial owner requirements in the Act will go further than the customer due diligence regulations; it will be interesting to see how they approach some of these questions.

    Conclusion

    The Corporate Transparency Act represents an important step in the right direction for the United States in the battle against money laundering and terrorist financing. It brings the United States into compliance with international anti-money laundering standards, which is an area where the United States—a pioneer of the anti-money laundering space—has arguably fallen behind.

    Authors

    Leigh-Alexandra Basha

    Partner

    Washington, DC

    Daniel J. Bell

    Partner

    Washington, DC

    Sebastian Orozco Segrera

    Partner

    Washington, DC, Miami

    More insights

  • Update Tenancy Law: Introduction of a Legal Presumption of Disturbance of the Business Basis

    Update Tenancy Law: Introduction of a Legal Presumption of Disturbance of the Business Basis

    ARTICLE / CLIENT ALERT

    Update Tenancy Law: Introduction of a Legal Presumption of Disturbance of the Business Basis

    December 15, 2020

    Read time: 2 min

    Key takeaways
    Overview

    The German government has indicated an amendment to commercial rental law regarding rent reductions during lockdown.

    In depth

    dfdfdf

    Authors

    Dr. Jens Ortmanns

    Partner

    Düsseldorf, Cologne

    Thomas A. Beisken, LL.M.

    Partner

    Düsseldorf

    Frank Müller

    Partner

    Frankfurt

    More insights

  • HRSA Releases Final Rule Establishing Dispute Resolution Process for the 340B Program

    HRSA Releases Final Rule Establishing Dispute Resolution Process for the 340B Program

    ARTICLE / CLIENT ALERT

    HRSA Releases Final Rule Establishing Dispute Resolution Process for the 340B Program

    December 14, 2020

    Read time: 7 min

    Key takeaways
    Overview

    On December 10, 2020, the Health Resources and Services Administration (HRSA) released a Final Rule to establish an administrative dispute resolution (ADR) process and ADR panels to resolve certain 340B Program disputes between drug manufacturers and 340B covered entities.

    The establishment of a 340B ADR process was mandated by the Affordable Care Act (ACA) more than 10 years ago. Nevertheless, the timing of the release has raised concerns regarding the effectiveness of the Final Rule in light of recent efforts by drug manufacturers to limit access to 340B drugs for dispensing under contracted pharmacy arrangements. Questions also remain as to when ADR panels will be established and begin hearing claims.

    In depth

    Background

    Development and Timing of the Final Rule

    The ACA requires the establishment of a binding ADR process for certain disputes between drug manufacturers and 340B covered entities arising under the 340B Program.

    In 2010, HRSA issued an advanced notice of proposed rulemaking requesting input on the development of the ADR process, followed in 2016 by a proposed rule describing the ADR process and requesting further comments. The proposed rule was subsequently withdrawn in 2017, making the release of the Final Rule, more than three years later, somewhat unexpected.

    The Final Rule

    340B ADR Panels

    The Final Rule establishes a 340B ADR Board (Board) consisting of at least six members appointed by the Secretary of HHS, with equal numbers of members from HRSA, the Centers for Medicare and Medicaid Services (CMS) and the HHS Office of General Counsel (OGC).

    For each claim brought to HRSA for review under the ADR process, the HRSA Administrator will select three members of the Board to form an ADR Panel, one each from HRSA, CMS and OGC. There will also be one ex-officio, non-voting member from the staff of the HRSA Office of Pharmacy Affairs (OPA).

    Jurisdiction

    The 340B ADR Panel’s jurisdiction is restricted two types of claims and any issues ancillary to these types of claims:

    1. 340B covered entities are permitted to bring claims that they have been overcharged for covered outpatient drugs by manufacturers.
    2. Drug manufacturers are permitted to bring claims that a covered entity has violated the 340B Program prohibition on diversion or duplicate discounts.

    Parties bringing claims before the 340B ADR Panel must generally do so within three years of the conduct giving rise to the claim and must seek damages exceeding $25,000, or seek equitable relief which will likely have a value of more than $25,000 during the 12-month period following the 340B ADR Panel’s decision.

    Unlike 340B covered entities, drug manufacturers seeking to bring claims are subject to certain conditions prior to adjudication. Consistent with the 340B statute, drug manufacturers may only bring claims following a formal audit of a covered entity, which requires use of an independent auditor and approval of the audit protocol by HRSA. HRSA expects drug manufacturers and covered entities to attempt (and document) good-faith resolution of disputes before bringing them to the ADR Panel for review.

    Joint or Consolidated Claims

    Covered entities are permitted to jointly file claims of overcharges by the same manufacturer for the same drug or drugs. Additionally, an association or organization may file consolidated claims of overcharges on behalf of multiple covered entities if each covered entity represented could file a claim against the manufacturer, is a member of the association or organization, and has agreed to the representation by the association or organization.

    Multiple manufacturers may request to consolidate claims against the same covered entity if the 340B ADR Panel determines that such consolidation is appropriate and consistent with the goals of fairness and economy of resources. However, in contrast to covered entities, associations or organizations representing the interests of drug manufacturers are not permitted to file consolidated claims on behalf of their members.

    Information Requests and Sanctions

    The 340B ADR Panel may request additional information from either party in a case. If a party fails to respond to an information request, the 340B ADR Panel may take actions such as:

    1. Holding facts to have been established in the proceeding
    2. Precluding a party from presenting or contesting a particular issue
    3. Excluding evidence
    4. Judgment in the proceeding or dismissal of proceeding.

    ADR Proceedings

    The 340B ADR Panel has discretion to determine the form and timeline of the ADR process. The Final Rule does require the 340B ADR Panel to conduct an evidentiary hearing when there are material facts in dispute. Further, unless the parties and the 340B ADR Panel agree otherwise, the Federal Rules of Civil Procedure and the Federal Rules of Evidence apply to the ADR proceedings.

    Final Agency Action

    Following the proceedings, the 340B ADR Panel members will decide whether a violation has occurred based on a preponderance of the evidence standard; that is, whether a violation is more likely to have occurred than not. The decision of a majority of the members of the 340B ADR Panel will be a precedential and binding final agency decision. The 340B ADR Panel will submit the final agency decision to all parties, and to HRSA for appropriate action regarding refunds, penalties, removal or referral to other appropriate federal authorities. Where appropriate, the 340B ADR Panel may make recommendations to HRSA for sanctions, including referrals to the HHS Office of Inspector General for its consideration of civil monetary penalties. Final decisions of the 340B ADR panel will be made public by HRSA and will be subject to judicial review under the Administrative Procedures Act.

    Key Takeaways

    Timing

    Although HRSA has not made any public statements addressing the timing of the Final Rule, it comes at a time when HRSA is under pressure to resolve the high-stakes contract pharmacy dispute between drug manufacturers and 340B covered entities. (Read more about this issue here.) 340B covered entities argue that drug manufacturers are openly violating the 340B statute and that HRSA has clear authority under the 340B statute to take punitive actions against drug manufacturers. While the ADR process could provide a venue to resolve the dispute, forcing 340B covered entities to rely on the ADR process could greatly prolong the path to resolution.

    Implementation

    Although the effective date of the Final Rule is January 13, 2021, it may be many months or years before covered entities and drug manufacturers are able to see results from the ADR process. Further, the Final Rule could be subject to legal challenges based on the delay between the proposed rule and the Final Rule, the use of the decisions as a method of rulemaking, or other procedural concerns.

    Formalized Process

    The Final Rule creates a significantly more formalized process for review and disposition of 340B Program compliance issues than has historically been undertaken by HRSA. The adoption of certain aspects of the Federal Rules of Civil Procedure Federal Rules of Evidence and establishment of a clear pathway to final agency action subject to judicial review pursuant to the Administrative Procedure Act will bring a materially different tone and structure to 340B Program oversight. This process contrasts with prior experiences under the existing 340B self-disclosure and audit processes, which are generally informal, as compared to other federal administrative review and adjudication processes.

    Back-Door Rulemaking

    The Final Rule is also notable in establishing that the decisions of the 340B ADR panel will be precedential and will address areas of 340B Program requirements for which HRSA does not have rulemaking authority. For example, the Final Rule identifies claims of diversion related to patient and covered entity eligibility (including whether a pharmacy is part of a covered entity) and claims of duplicate discounts arising as to Medicaid Managed Care claims as within the scope of the 340B ADR Panel. This raises concerns that the decisions of the 340B ADR Panel could be used by HRSA as a “back door” to creating binding requirements for 340B Program compliance that it could not otherwise impose without a change in the 340B statute granting HRSA rulemaking authority over 340B diversion and duplicate discount requirements, subject to potential vulnerability to legal challenge.

    Authors

    Emily Jane Cook

    Partner

    Los Angeles, Washington, DC

    Cathy Ren

    Partner

    Los Angeles

    Steven J. Schnelle

    Partner

    New York – One Vanderbilt Avenue

    More insights

  • ‘Icy’ Guidance on Polaroid Factors: Second Circuit Notes Lack of Direction Regarding how Much Weight to Give Each Factor

    ARTICLE

    ‘Icy’ Guidance on Polaroid Factors: Second Circuit Notes Lack of Direction Regarding how Much Weight to Give Each Factor

    December 14, 2020

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors
    More insights

  • Leading Digital and Cybersecurity Risk Factor Disclosures for SEC Registrants

    Leading Digital and Cybersecurity Risk Factor Disclosures for SEC Registrants

    ARTICLE

    Leading Digital and Cybersecurity Risk Factor Disclosures for SEC Registrants

    December 14, 2020

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors
    More insights

  • SEC Staff Bulletin Highlights AML Risks Associated with Low-Priced Securities Trading in Omnibus Accounts

    SEC Staff Bulletin Highlights AML Risks Associated with Low-Priced Securities Trading in Omnibus Accounts

    ARTICLE / CLIENT ALERT

    SEC Staff Bulletin Highlights AML Risks Associated with Low-Priced Securities Trading in Omnibus Accounts

    December 14, 2020

    Read time: 9 min

    Key takeaways
    Overview

    On Nov. 12, 2020, the staff of the U.S. Securities and Exchange Commission’s (“Commission”) Division of Trading and Markets (“Division Staff”) issued a bulletin (“Bulletin”) highlighting various anti-money laundering (“AML”) risks for broker-dealers effecting low-priced securities transactions through omnibus accounts maintained for foreign financial institutions.[1] Historically, FinCEN and the Division Staff have recognized that omnibus accounts are an integral part of the way in which firms do business,[2] but have also raised concerns about how such accounts can be misused.[3] This new Bulletin focuses in particular on the risks of such accounts involving foreign financial institutions and trading in low-priced securities. However, the Division Staff also noted that wrongdoers can engage in illicit activities through any means that allow a nominee account holder to conceal the identity of the ultimate beneficial owner of the account holder.

    Background and Current Regulatory Framework

    Over the past few years, the Commission has brought numerous enforcement actions against parties who allegedly perpetrated multi-layered schemes to defraud investors involving low-priced securities. These schemes were set up by foreign individuals or groups of individuals who obtained a controlling interest in issuers by acquiring large quantities of their low-priced securities. These individuals or groups typically held less than 5% of the controlling interest in issuers and set up nominee accounts and multiple layers of foreign financial intermediaries to conceal their actions. Given the omnibus account structures, these individuals were able to shield their identities from U.S. broker-dealers, with the U.S. broker-dealer only knowing the identity of the foreign financial institution and not the identity of the foreign financial institution’s underlying customers and/or ultimate beneficial owners.

    The Division Staff believes that foreign financial institutions engaged in low-priced securities trading through omnibus accounts present a high risk for illicit activities, including fraud, money laundering and unregistered securities offerings. The Bulletin articulates the Division Staff’s concern that U.S. broker-dealers may be facilitating this kind of illicit activity by not sufficiently discharging their AML obligations, failing to conduct sufficient due diligence on omnibus accounts held for foreign financial institutions, and ignoring (or failing to report) red flags associated with illicit or suspected suspicious activity conducted through these accounts.

    The Bulletin also reminds broker-dealers of their existing obligations under the Bank Secrecy Act[4] (“BSA”), Rule 17a-8 of the Exchange Act, and Section 5 of the Securities Act of 1933 (“Securities Act”), as well as FINRA rules, with respect to AML compliance when effecting low-priced securities transactions through omnibus accounts maintained for foreign financial institutions.

    Analysis

    Broker-dealers are advised to consider three key AML obligations when engaging in transactions in low-priced securities effected through omnibus accounts, especially when those accounts are maintained for foreign financial institutions.

    First, the BSA requires broker-dealers to establish a risk-based, written AML program with policies, procedures and internal controls reasonably designed to detect and report suspicious activities, including a relatively new fifth-pillar of the AML program.[5]

    Second, as part of their AML program, broker-dealers must establish a risk-based, written due diligence program for “correspondent accounts”[6] held for a foreign financial institution, including omnibus accounts associated with low-priced securities transactions, as part of their obligations under Section 312 of the USA PATRIOT Act[7] (“Special Due Diligence Program”). In high-risk situations involving any correspondent account, an AML program should include provisions for obtaining any necessary and appropriate information about the customers underlying such an account.

    Finally, broker-dealers should consider whether a transaction conducted or attempted by, at, or through a broker-dealer that involves, individually or in aggregate, funds or other assets of at least $5,000, requires reporting to FinCEN on a suspicious activity report (“SAR”).[8]

    Intersection with CIP and CDD Obligations

    FinCEN and the Commission have previously issued joint guidance clarifying that in circumstances associated with omnibus account relationships, the broker-dealer’s “customer,” for purposes of the customer identification program (“CIP”) and customer due diligence (“CDD”) rules, would be the financial institution intermediary and not the financial institution’s underlying customer and/or the ultimate beneficial owner of the securities.[9] The Bulletin cautions, though, that “it is critical for broker-dealers to remember that even when the ultimate beneficial owner is not a broker-dealer’s ‘customer’ for CIP and CDD purposes, there are circumstances where the characteristics of that ultimate beneficial owner would need to be considered as part of the broker-dealer’s broader AML obligations” and that “broker-dealers may determine that a foreign financial institution presents a higher-risk profile and, accordingly, collect additional information to better understand the customer relationship.”

    Division Staff Views Regarding Application of AML Obligations to Foreign Omnibus Accounts

    Notwithstanding the existing CIP and CDD guidance regarding omnibus accounts, broker-dealers should be aware that the Division Staff considers an inability to obtain information identifying the ultimate beneficial owners of funds and securities held in an omnibus account engaging in higher-risk transactions (such as low-priced securities transactions) to significantly increase the AML and other legal and compliance risks of the foreign omnibus account associated with those transactions. The Bulletin suggests that broker-dealers should consider obtaining information regarding the characteristics of ultimate beneficial owners of funds and securities, including their identities, when due diligence procedures identify those transactions or entities as posing a heightened risk. If a broker-dealer determines that such inquiries fail to appropriately manage the risk, then they should consider refusing to open (or closing) omnibus accounts, or restricting or rejecting transactions where necessary to mitigate that risk. The Bulletin reminds broker-dealers that “nothing under the federal securities laws or FINRA rules obligates [broker-dealers] to accept an order where they believe that the associated compliance or legal risks are unacceptable.”

    The Bulletin also provides an illustrative example fact pattern, typifying the chain of events that groups have used to engage in illicit activities involving low-priced securities. The Division Staff notes that this pattern varies and includes various combinations of the following components and others:

    • Obtain Controlling Interest in an Issuer
      • First, an individual or group of individuals (“Control Group”) obtains a controlling interest in an issuer through the purchasing of a large quantity of low-priced securities without a restrictive legend.
    • Transfer to Nominees
      • Next, the low-priced securities are transferred to offshore entity nominees with foreign ownership, that have no apparent purpose other than concealing the Control Group. The securities are then distributed such that no nominee holds account-level positions of 5% of the total issued and outstanding securities, to evade detection and identification of the Control Group.
    • The Accounts are Layered Through “Nested” Account Relationships
      • The Control Group opens multiple accounts on behalf of the nominees at a series of foreign intermediaries. The foreign intermediaries use omnibus accounts in their names at other foreign intermediaries to execute trades as instructed by, and for the benefit of, the Control Group.
      • There may be multiple layers of foreign intermediaries handling the order flow through successive account relationships prior to the trades being consolidated and executed with a U.S. broker-dealer.
    • Foreign Financial Institutions Execute Trades at U.S. Broker-Dealer(s)
      • Finally, the foreign financial institutions execute trades through their omnibus accounts at U.S. broker-dealers. To reduce scrutiny, and avoid raising red flags, the Control Group may use a network of foreign financial institutions and U.S. broker-dealers such that no entity has complete visibility into the amount of securities deposited, trading volume and activity, timing of wire transfers, etc.

    Thus, through layering the accounts and spreading the trading activity, the Control Group is able to obfuscate the ultimate beneficial owners’ identities and engage in fraudulent schemes (e.g., coordinated manipulative trading, fraudulent stock promotion, “pump and dump” schemes, etc.) undetected.

    Other Risks and Related Broker-Dealer Obligations

    The Bulletin also reminds broker-dealers of their obligations (1) to conduct a reasonable inquiry when selling securities in an unregistered transaction in reliance on Section 4(a)(4) of the Securities Act; and (2) pursuant to sanctions imposed by OFAC.

    With regard to reasonable inquiry, Section 5 of the Securities Act requires all offers and sales of securities in interstate commerce to be registered, absent an applicable exemption. Section 4(a)(4) of the Securities Act provides such an exemption for “brokers’ transactions executed upon customers’ orders on any exchange or in the over-the-counter market but not the solicitation of such orders.”[10] However, in order to claim this exemption, broker-dealers must conduct a reasonable inquiry to ensure that the account’s owner is not an underwriter of the securities and that the transaction is not part of an issuer’s distribution.[11] Because of the risks associated with transactions in low-priced securities effected through omnibus accounts maintained for foreign financial institutions, the Bulletin suggests that broker-dealers should consider whether to obtain identifying information as to the ultimate beneficial owners of funds and securities. If a broker-dealer determines that obtaining this identifying information is appropriate but is unable to obtain it, then that broker-dealer should consider whether to proceed with the transaction.

    With regard to OFAC, the Bulletin reminds broker-dealers of their sanctions-related obligations, including the requirements related to the (i) blocking of accounts and other property interests of entities and individuals appearing on sanctions lists, including of entities owned (directly or indirectly) 50% or more by blocked persons; (ii) country-based sanctions prohibitions; and (iii) rejecting of prohibited transactions. In addition, it provides that OFAC maintains several sanctions programs that prohibit U.S. persons, including broker-dealers, from dealing in equity and debt of, and extension of credit to, certain sanctions targets.

    Lastly, the Bulletin highlights a nonexclusive list of key red flags for broker-dealers from FINRA Regulatory Notice 19-18, including, among others:

    • Accounts opened in the name of foreign financial institutions that sell shares of stock on an unregistered basis on behalf of customers;
    • Sudden spike in investor demand for, coupled with a rising price in, a thinly traded or low-priced security; and
    • Customers domiciled in, doing business in or regularly transacting with counterparties in a jurisdiction that is known as a bank secrecy haven, tax shelter, high-risk geographic location or conflict zone.[12]

    Conclusion

    Issues relating to omnibus accounts continue to raise concerns with the SEC and now FinCEN. As noted above, prior guidance and prior enforcement actions have demonstrated that concern. Going forward, firms will have to tread carefully when applying the omnibus guidance in the context of low-priced securities. Managing the particular issues presented in heightened risk activities may require evaluating or modifying existing AML compliance programs, as well as accounting for the additional risks posed by transactions routed through multiple layers of accounts.


    Authored by Julian Rainero, Betty Santangelo, Derek N. Lacarrubba, Melissa G.R. Goldstein, and J. Eric Prather.

    If you have any questions concerning this Alert, please contact your lawyer or one of the authors.

    In depth
    Authors

    Betty Santangelo

    Counsel

    New York – 919 Third Avenue

    Melissa G.R. Goldstein

    Partner

    New York – 919 Third Avenue

    J. Eric Prather

    Associate

    New York – 919 Third Avenue

    More insights

  • A Lawyer’s Guide to MAZE Ransomware Attacks

    A Lawyer’s Guide to MAZE Ransomware Attacks

    ARTICLE

    A Lawyer’s Guide to MAZE Ransomware Attacks

    December 11, 2020

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors
    More insights

  • Innovating Our Way Out of a Crisis

    ARTICLE

    Innovating Our Way Out of a Crisis

    December 10, 2020

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors

    H. Michael Byrne

    Partner

    New York – One Vanderbilt Avenue

    More insights